Sofie Joris

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families

Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon et al. · BMC Cancer · 2019 · 51 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

Sofie Joris, Hannelore Denys, Joëlle Collignon et al. · ESMO Open · 2023 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma

Odrade Gondry, Vicky Caveliers, Catarina Xavier et al. · Journal of Nuclear Medicine · 2024 · 40 citations · Full text

Medicine, Oncology, Radiology +17

Frequent incidence of <i><scp>BARD1</scp></i>‐truncating mutations in germline <scp>DNA</scp> from triple‐negative breast cancer patients

Sylvia De Brakeleer, Jacques De Grève, Christine Desmedt et al. · Clinical Genetics · 2015 · 30 citations

Medicine, Genetics, Oncology +17